Abeona Therapeutics (ABEO): Undervalued Pipeline - FBR

September 21, 2016 9:16 AM EDT
Get Alerts ABEO Hot Sheet
Price: $5.15 -11.21%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ABEO Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Abeona Therapeutics (NASDAQ: ABEO) and believes recent activities by ABEO continue to show progress being made with its pipeline of rare disease candidate therapies and emerging preclinical assets. He thinks that ABEO's value could quickly accelerate in the coming months and reiterated his price target of $15.

EB-101 is a skin graft product that corrects for the absence of the Type VIII collagen gene (COL7A1), which is advancing with the announcement of the fifth patient enrolled in the Phase I/II clinical trial in recessive dystrophic epidermolysis bullosa (EB). The analyst thinks that this could be a major driver of ABEO's stock value.

For an analyst ratings summary and ratings history on Abeona Therapeutics click here. For more ratings news on Abeona Therapeutics click here.

Shares of Abeona Therapeutics closed at $5.78 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment